# Veeva Systems (VEEV) Sector: Software (life sciences cloud) | Field | Value | |---|---| | Price | $305.55 | | Market cap | $49B | | Intrinsic value source | Analysts | | Data as of | 2026-11-11 | | Next earnings | 2026-12-02 (estimate) | Analysts: Bullish Picks: Research only Discount category: Pricey ## In short Veeva's price already includes that it keeps most CRM customers while it moves them off the Salesforce platform, and only more Vault CRM wins with steady R&D software growth can support this price. ## Themes and gap - Themes: AI disruption risk (ai-disruption), New management (management-change) - Gap type: Slow (slow) - Why: Veeva moves its CRM customers to Vault CRM until the end of 2029, so each quarter's wins and losses against Salesforce and the AI products close the gap only over several years. ## About Veeva Systems Inc. (Veeva) sells cloud software, data and consulting to the life sciences industry. Its Commercial Solutions include CRM software for sales teams, such as Vault CRM and the older Veeva CRM, and customer and market data. Its R&D Solutions on the Veeva Vault platform manage clinical trials, regulatory filings, drug safety and quality. It also sells AI agents, such as Veeva AI and Veeva Falcon. Veeva has more than 1,500 customers, from the largest drug makers to small biotech companies. Revenue was $3,195 million in fiscal year 2026, which ended on January 31, 2026, and $928.0 million in Q2 of fiscal year 2027. Veeva is a Public Benefit Corporation. The head office is in Pleasanton, California. Peter Gassner is Chief Executive Officer. ## Thesis Veeva's price already includes years of steady growth. Veeva must move its CRM customers from the Salesforce platform to Vault CRM by the end of 2029, and Salesforce now competes for these customers. Some large customers chose Salesforce. Investors also ask whether AI agents will change how drug makers buy software. For the price to hold, three things must be true. Vault CRM must keep winning large drug makers, after 12 of the top 20 committed by August 2026. The R&D and quality products must keep growing fast. And new AI products such as Veeva Falcon must add revenue without lowering the price of the existing products. The Q3 fiscal 2027 report, expected in early December 2026, and the fiscal 2028 guidance, expected in early March 2027, are the next tests. ## Checkpoints - Aug 26, 2026: Q2 fiscal 2027 results: growth and Vault CRM wins. Status: Passed. Watch: Revenue at or above guidance and more top 20 Vault CRM commitments pass; a miss or lost large customers fail. Outcome: Revenue rose 18% and beat guidance, and top 20 commitments to Vault CRM rose to 12. - Dec 2, 2026 (estimate): Q3 fiscal 2027 results. Status: Pending. Watch: Revenue at or above $935 million and non-GAAP EPS at or above $2.34 pass; results below the guidance fail. - Mar 2027 (estimate): Q4 fiscal 2027 results and fiscal 2028 guidance. Status: Pending. Watch: Fiscal 2028 guidance for revenue growth of about 12% or more passes; lower guidance or more CRM losses fail. ## Balance sheet - Cash: $7.2B - Debt: $0.0M - Net cash: $7.2B Veeva has no debt. At July 31, 2026, cash and cash equivalents were $1,812 million and short-term investments were $5,431 million, a total of $7,243 million. Deferred revenue was $1,310 million, because customers pay for annual subscriptions in advance, mostly in the first quarter of the fiscal year. Lease liabilities were $152 million. Net cash from operating activities was $1,366 million in the first half of fiscal 2027. In the same period, Veeva bought back 2,663,443 shares for about $467 million, and $1.4 billion of the $2 billion program remained. At August 25, 2026, there were 161,908,850 Class A common shares. As of 2026-07-31. Sources: - https://www.sec.gov/Archives/edgar/data/1393052/000139305226000036/veev-20260731.htm - https://www.sec.gov/Archives/edgar/data/1393052/000139305226000032/veev-20260731xex991.htm ## Dividends Veeva Systems does not pay a dividend. Source: company filings and market data, read on 2026-11-10. ## Recent events - 2026-11-05: At its Investor Day, Veeva said that it expects Q3 fiscal 2027 results to meet or exceed its guidance of revenue of $932 million to $935 million and non-GAAP EPS of $2.33 to $2.34. - 2026-08-26: Veeva reported Q2 fiscal 2027 results. Revenue rose 18% to $928.0 million, and non-GAAP EPS was $2.35. Veeva raised its fiscal 2027 guidance to revenue of $3,682 million to $3,687 million and non-GAAP EPS of about $9.21. It said that 12 of the top 20 drug makers committed to Vault CRM, and it bought Copli. - 2026-08-20: Veeva said that Thomas Schwenger, President and Chief Customer Officer, would leave on October 2, 2026 to become CEO of a Veeva partner. Dan Rizzo became EVP, Sales, Consulting, and Services. - 2026-04-20: Veeva said that its General Counsel, Josh Faddis, would retire on November 1, 2026 and become a part-time advisor. - 2026-03-04: Veeva reported fiscal 2026 results. Revenue rose 16% to $3,195.3 million, and non-GAAP EPS rose to $8.10 from $6.60. - 2026-01-05: Veeva's board authorized share repurchases of up to $2 billion. ## Latest news and filings - Last earnings: 2026-11-06 (8-K: https://www.sec.gov/Archives/edgar/data/1393052/000139305226000039/) - Next earnings: 2026-12-02 (expected; the company has not confirmed it) | Filed | Form | Headline | Period end | XBRL document | Link | | --- | --- | --- | --- | --- | --- | | 2026-11-06 | 8-K | Earnings release | | veev-20261105 | https://www.sec.gov/Archives/edgar/data/1393052/000139305226000039/ | | 2026-08-27 | 10-Q | Quarterly report for the period ended Jul 31, 2026 | 2026-07-31 | veev-20260731 | https://www.sec.gov/Archives/edgar/data/1393052/000139305226000036/veev-20260731.htm | | 2026-08-26 | 8-K | Earnings release | | veev-20260826 | https://www.sec.gov/Archives/edgar/data/1393052/000139305226000032/ | | 2026-08-20 | 8-K | Change of directors or officers | | | https://www.sec.gov/Archives/edgar/data/1393052/000121390026092096/ea0302765-8k_veeva.htm | | 2026-06-18 | 8-K | Shareholder vote results | | veev-20260617 | https://www.sec.gov/Archives/edgar/data/1393052/000139305226000029/veev-20260617.htm | | 2026-06-05 | 10-Q | Quarterly report for the period ended Apr 30, 2026 | 2026-04-30 | veev-20260430 | https://www.sec.gov/Archives/edgar/data/1393052/000139305226000026/veev-20260430.htm | | 2026-06-03 | 8-K | Earnings release | | veev-20260603 | https://www.sec.gov/Archives/edgar/data/1393052/000139305226000022/ | | 2026-04-20 | 8-K | Change of directors or officers | | veev-20260420 | https://www.sec.gov/Archives/edgar/data/1393052/000139305226000018/veev-20260420.htm | | 2026-03-20 | 10-K | Annual report for the period ended Jan 31, 2026 | 2026-01-31 | veev-20260131 | https://www.sec.gov/Archives/edgar/data/1393052/000139305226000014/veev-20260131.htm | | 2026-03-04 | 8-K | Earnings release | | veev-20260304 | https://www.sec.gov/Archives/edgar/data/1393052/000139305226000007/ | Every filing on SEC EDGAR (CIK 1393052): https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001393052&type=&dateb=&owner=include&count=40 ## Risks - High: Veeva must move its CRM customers to Vault CRM, because its agreement with Salesforce ended on September 1, 2025. Veeva supports Veeva CRM until December 31, 2029. Salesforce competes for these customers, and some large customers committed to Salesforce. - Medium: AI agents can change how drug makers buy and use software. If customers need fewer users or new rivals offer AI tools, revenue per customer can fall. - Medium: All customers are in the life sciences industry. Lower drug prices, mergers of drug makers or cuts in research budgets reduce spending on software. - Low: Senior people changed in 2026: the President and Chief Customer Officer left in October, and the General Counsel retired in November. - Low: Stock-based compensation was $256 million in the first half of fiscal 2027. Share buybacks offset part of the dilution. ## Links - Page: https://picks.utilarium.app/company/VEEV/ - History of changes: https://picks.utilarium.app/company/VEEV/history/ - JSON with full history: https://picks.utilarium.app/data/company/VEEV.json > Picks is a personal record of stock picks. It gives general opinions about stocks, including a "Top pick" label. They are not tailored to your needs, goals or risk tolerance. Kevin is not a registered adviser and relies on the general-advice exemption in Canadian securities law (NI 31-103 s.8.25). Do your own research, or ask a registered adviser. Kevin may hold any stock on this site. Prices, intrinsic values and ratings can be delayed or wrong; check the original source. Full disclaimer: /disclaimer/.